Tag Archives: anxiety

Borderline Personality Disorder Common in Pain Patients

Borderline Personality Disorder Common in Chronic Pain Patients – MedScape – by Fran Lowry – Mar 2020

A significant proportion of patients who suffer from chronic pain also have features of borderline personality disorder (BPD), new research shows.

I really don’t know what to think about this because our healthcare system is so strongly biased against chronic pain patients and opioids that I don’t trust most of the research on it these days.

I can’t help but notice that it only says that pain patients “have features of” the disorder, but not that they have it. This is a sly way to make it sound like we all have BPD. Continue reading

Psychiatric Disorders From Ehlers–Danlos Syndrome

Nationwide population-based cohort study of psychiatric disorders in individuals with Ehlers–Danlos syndrome or hypermobility syndrome and their siblings | BMC Psychiatry | Full Text – 04 July 2016

It looks like we inherit not only chronic physical pain but also a fourfold increased risk of both anxiety and depression.

Somehow, it makes sense to me that having a body “too loose” and being physically “unstable” would also manifest as being mentally “unstable”, that along with our physical pain, we also suffer from mental pain.

Abstract

To assess the risk of psychiatric disorders in Ehlers-Danlos syndrome (EDS) and hypermobility syndrome.   Continue reading

Sensory Over-Responsivity and ADHD

Sensory Over-Responsivity and ADHD: Differentiating Using Electrodermal Responses, Cortisol, and Anxiety – Free full-text /PMC2885866/Mar 2010

This study describes a symptom of ADHD, sensory over-responsivity (SOR), that also seems prevalent with EDS: oversensitivity, both physical and emotional.

Deficits in sensory modulation have been linked clinically with impaired attention, arousal, and impulsivity for years, but a clear understanding of the relationship between sensory modulation disorders and attention deficit hyperactivity disorder (ADHD) has proven elusive.”

The phrase “deficit in sensory modulation” describes what I feel when I can’t tune out anything going on around me and get snagged on every feeling passing through me. It’s very hard to make my feelings “shut up and behave.”  Continue reading

Neurosteroids for Anxiety Disorders

Neuroactive Steroid Levels in Patients With Generalized Anxiety DisorderThe Journal of Neuropsychiatry and Clinical Neurosciences – 2001

Anxiety isn’t just a state of mind, it’ s physical state of the body too.

Several neurotransmittersystems have been suspected to play a role in the pathophysiology of GAD [generalized anxiety disorder].  Various lines of research suggest dysregulation of the gamma-aminobutyric acid (GABA A )/ benzodiazepine (BZ) receptor complex.

These findings include decreased numbers and sensitivities of BZ receptors in patients with GAD and successful pharmacologic treatment of GAD with agents that target the GABA A / BZ receptor (e.g., benzodiazepines).   Continue reading

Anxiety Disorders Linked to Mitochondria

Anxiety Disorders Linked to Disturbances in the Cells’ Powerhouses [Mitochondria]  19-Sep-2019 1 Newswise

The powerhouse of the cell, the mitochondria, provides energy for cellular functions. But those activities can become disturbed when chronic stress leads to anxiety symptoms in mice and humans. Iiris Hovatta of the University of Helsinki and colleagues report these findings in a new study published 26th September in PLOS Genetics.

Chronic stress due to stressful life events, such as divorce, unemployment, loss of a loved one and war, are a major risk factor for developing panic attacks and anxiety disorders. 

This is not only proven, but also intuitively true, as we know from our own lives, once beset by chronic pain.  Continue reading

Fear and Anxiety: A Two-System Framework

Using Neuroscience to Help Understand Fear and Anxiety: A Two-System Framework. – PubMed – NCBI – Am J Psychiatry. Nov 2016

This makes sense to me because my anxiety isn’t specific like fear is. When I’m anxious, whatever I’m thinking about makes my stomach clench with dread, but when I’m afraid, I fear a specific situation.

Tremendous progress has been made in basic neuroscience in recent decades. One area that has been especially successful is research on how the brain detects and responds to threats.

Such studies have demonstrated comparable patterns of brain-behavior relationships underlying threat processing across a range of mammalian species, including humans.

This would seem to be an ideal body of information for advancing our understanding of disorders in which altered threat processing is a key factor, namely, fear and anxiety disorders.

But research on threat processing has not led to significant improvements in clinical practice.

The authors propose that in order to take advantage of this progress for clinical gain, a conceptual reframing is needed.

Key to this conceptual change is recognition of a distinction between circuits underlying two classes of responses elicited by threats:

1) behavioral responses and accompanying physiological changes in the brain and body and

2) conscious feeling states reflected in self-reports of fear and anxiety.

This distinction leads to a “two systems” view of fear and anxiety.

The authors argue that failure to recognize and consistently emphasize this distinction has impeded progress in understanding fear and anxiety disorders and hindered attempts to develop more effective pharmaceutical and psychological treatments. The two-system view suggests a new way forward.

Circuitry for Fearful Feelings, Behavior Untangled in Anxiety Disorders PubMed – NCBI – Sep 2016 • Science Update

An “incorrect” assumption that fear and anxiety are mediated in the brain by a single “fear circuit” has stalled progress in developing better treatments for anxiety disorders, argue two leading experts. Designing future research based on a “two-system” framework holds promise for improving treatment outcomes, say Daniel Pine, M.D.

Neuroscience advances in understanding how the brain detects and responds to threat have failed to translate into significantly improved treatments because the field has been led astray by a simplistic notion of a “fear system,” contend Pine and LeDoux.

For example, hopes that medications that lessen rodents’ stress reactivity might help people feel less fearful or anxious often haven’t borne out.

It seems absurd to try modeling disorders that stem from human brain function, like anxiety, depression, or addiction, in rodents. Chronic pain cannot be modeled in animals if it really is a biopsychosocial disorder as many claim.

They can’t say “psychological and sociological factors greatly influence pain perception” and then cite pain studies that were done on animals.

Rather, the authors point to mounting evidence that such subjective feeling states are mediated via different circuitry than defensive behaviors. The former via higher order processing in the cortex – and the latter via the amygdala and related centers, mostly deeper in the brain.

Fear and anxiety describe conscious subjective feeling states; defensive reactions refer to rapidly-deployed behaviors or physiological responses.

Fear denotes feelings associated with an imminent threat, anxiety feelings associated with an uncertain or more distant source of harm.

For example, the amygdala, often colloquially dubbed the brain’s “fear center,” in fact unconsciously detects and responds to imminent threats and contributes to fear only indirectly.

States like fear and anxiety instead arise from areas of the cortex associated with higher order thinking processes and language in people, only some of which occur in other animals.

It’s hard to imagine a rat with anxiety about how they’re going to pay for retirement, or how they’re going to find affordable housing. Yet these are precisely the kinds of thoughts that can trigger my anxiety.

If feelings of fear or anxiety are not products of circuits that control defensive behavior, studies of defensive behavior in animals will be of limited value in finding medications that can relieve feelings of fear and anxiety in people,” observe the authors, who note that making such distinctions will help in the design of more realistic translational studies.

the experience of fear and anxiety is rooted in cortical changes in thinking, attention and memory, some “anxiolytic” effects might result from “general emotional blunting” or “impaired cognitive processing,” they add.

Improving treatments will require a more exact understanding of how treatments work. With this knowledge and the two-systems perspective, existing treatments might be adapted to work better. Brain imaging biomarkers might help tailor treatments to target circuit dysfunctions of specific patients.

Pregabalin (Lyrica) for Anxiety

Because I’m plagued by anxiety, I’m always interested in any unorthodox methods of dealing with it. While “benzos” would work for the immediate problem, I can’t (and am not allowed to with my opioids) take them all the times I’m anxious.

With all my researching, I’m surprised to discover that I missed a solution that seems obvious in retrospect: the Lyrica I’m prescribed, which I take on an “as needed” basis for a certain kind of pain, can also act as an anti-anxiety medication.

Here are a couple of PubMed abstracts showing that Lyrica (pregabalin) has been evaluated for anxiety for years already: Continue reading

The Diagnosis and Treatment of Anxiety Disorders

The Diagnosis and Treatment of Anxiety Disorders – free full-text /PMC6206399/ Sep 2018 

Background

Anxiety disorders are the most common type of mental illness in Europe, with a 12-month prevalence of 14% among persons aged 14 to 65.

Their onset is usually in adolescence or early adulthood. The affected patients often develop further mental or somatic illnesses (sequential comorbidity).

Methods

This review is based on pertinent publications retrieved by a selective search in PubMed.   Continue reading

Neurosteroids: Endogenous Role in Human Brian

Neurosteroids: Endogenous Role in the Human Brian and Therapeutic Potentials – free full-text /PMC3139029/ – July 2011

This chapter provides an overview of neurosteroids, especially their impact on the brain, sex differences and therapeutic potentials.

Neurosteroids are synthesized within the brain and rapidly modulate neuronal excitability. Neurosteroids such as allopregnanolone are positive allosteric modulators of GABA-A receptors with powerful antiseizure activity in diverse animal models.

Neurosteroids increase both synaptic and tonic inhibition. They are endogenous regulators of seizure susceptibility, anxiety and stress.

This is exactly the kind of information I was looking for: a potential new treatment for the anxiety that has tormented me for decades.  Continue reading

Neurosteroids in the Treatment of Anxiety

Neurosteroids as Neuromodulators in the Treatment of Anxiety Disorders free full-text /PMC3356011/ – Front Endocrinol (Lausanne). Oct 2011

Anxiety disorders are the most common psychiatric disorders. They are frequently treated with benzodiazepines, which are fast acting highly effective anxiolytic agents. However, their long-term use is impaired by tolerance development and abuse liability.

In contrast, antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are considered as first-line treatment but have a slow onset of action.

Neurosteroids are powerful allosteric modulators of GABAA and glutamate receptors. However, they also modulate sigma receptors and they are modulated themselves by SSRIs.   Continue reading